I love when people use excuses such as, "This is a triple

New Post Public Reply Private Reply Replies (0) Message Board
joey68
I love when people use excuses such as, "This is a triple zero stock for a reason; it sucks".

That excuse would imply that every stock with three zeros 'sucks'.

Funny.. how come on February 18, 2016 I invested in a stock at .0007 and by March 23 of the same year, it jumped to .0092? That was a 1215% PROFIT for me in under two months. I thought 'triple zero' stocks sucked??

So you see, the number of zeros in a stock is not an indication of utter and complete failure. In fact, many people make the most profits by investing in promising companies down here. and why? As an example, if someone invests $1000 at .0003 they get 3,333,333 shares.

By not investing more than they can afford to lose, it doesn't take much upward movement to create a decent profit. In fact, in the above example, if the stock went to .0007, that's a $983 profit after tax; pretty darn good for a .0004 increase in share price. of course, every stock has the potential to not increase in price, which is why DD is so important.

I don't think its the number of zeros that necessarily determine a 'good' or 'bad' investment. its more along the lines of whether or not the investor has the fortitude to know when to sell at the correct time, not investing more than they can afford to lose, and not being money hungry by constantly buying millions upon millions of shares in one company.

Not investment advice.

REVE Technologies, Inc. (BSSP) Stock Research Links

BSSP Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 185

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 170

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 234

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 155

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 143

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 321

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 139

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 249

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 230

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 313

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading

Top 5 Most Recently Viewed Articles

Healthcare Realty Trust's Q4 Highlights and Dividend Update

Updated Category News Views 112

Healthcare Realty Trust Quarterly Results Overview Healthcare Realty Trust Incorporated (NYSE: HR) has reported its fourth quarter results for the year 2024, highlighting significant developments in its operations and financial performance. The company recorded a net (loss) income attributable to common stockholders of $(106.8) million, or $(0.31) per diluted share,...

Continue Reading
BGL's Strategic Move: Selling Western Botanicals to Riverside

Updated Category News Views 322

Brown Gibbons Lang & Company (BGL) has just sealed the deal on a significant sale—Western Botanicals, a prominent player in the Vitamins, Minerals, and Supplements (VMS) contract development and manufacturing space, is headed to The Riverside Company. Now this isn’t just another corporate shuffle; it's BGL’s third foray into the CDMO subsector and marks their fourth...

Continue Reading
High Arctic Energy Services Reports Second Quarter 2025 Success

Updated Category News Views 225

High Arctic Energy Services Reports Strong Second Quarter Results High Arctic Energy Services Inc. (TSX: HWO), a noted energy services provider, has recently shared its financial results for the second quarter of 2025, highlighting a continued commitment to operational excellence amid challenging market conditions. 2025 Second Quarter Performance Overview The company...

Continue Reading
DXC Technology Investors Notified of Securities Class Action

Updated Category News Views 45

DXC Technology Class Action Notice for Shareholders The Gross Law Firm has released an important notice for shareholders of DXC Technology Company (NYSE: DXC). This notice is aimed at individuals who acquired shares during the specified class period. Shareholders are encouraged to reach out to the firm if they are interested in being considered for the role of lead...

Continue Reading
Manulife's $750M US Offering: Risky or Strategic?

Updated Category News Views 50

Manulife: Debuting $750M in Subordinated Notes When it comes to Manulife's latest move, it's all about the numbers. They've priced a U.S. public offering of a meaty $750 million in subordinated notes at an enticing 6.146% interest rate. That's no pocket change, folks, and it highlights a strategy or a gamble, depending on your view. But here's the kicker: these notes may...

Continue Reading